<DOC>
	<DOCNO>NCT01402193</DOCNO>
	<brief_summary>The purpose study compare TGF-β1 change concomitant sequential Arimidex postmenopausal woman breast cancer , measure proportion patient elevation TGF-β1 level 4th week initiation radiotherapy relative pre-treatment baseline .</brief_summary>
	<brief_title>Study Arimidex Radiotherapy Sequencing</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Provision inform consent Pathological confirmation breast cancer ER ( + ) and/or PR ( + ) . Postmenopausal woman Age≤70 year old Breast conservative surgery axillary dissection stag either sentinel node biopsy axillary sample Postmastectomy patient T1T2 N1N3 , T3T4 N Negative surgical margin Karnofsky≥70 Laboratory criterion : PLT≥100*109/L WBC≥4000/mm3 HGB≥10g/dl ALT AST &lt; 2*ULN No presence metastatic disease No malignant tumour Presence metastatic disease . T1 , T2 , N0 mastectomy Noninfiltrative breast carcinoma underwent mastectomy Other malignant tumor ( concurrent previous ) . Positive surgical margin . Patients demonstrate hypersensitivity Arimidex excipient . Patients severe renal impairment ( creatinine clearance le 20 ml/min ) . Patients moderate severe hepatic disease . Oestrogencontaining therapy coadministered Arimidex would negate pharmacological action . Not able willing sign inform consent Autoimmune diseases include scleroderma , systemic lupus erythematosus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Timing Radiotherapy</keyword>
	<keyword>TGF-beta1</keyword>
</DOC>